Ivonescimab just beat the drug that defined the biliary tract cancer standard of care: the Phase III HARMONi-GI1 study met its primary endpoint of overall survival, with ivonescimab plus chemotherapy outperforming durvalumab plus chemotherapy in previously untreated advanced biliary tract cancer. That is not a surrogate endpoint win dressed up as meaningful. That is a head-to-head OS readout against an active comparator, which is the hardest evidentiary bar a trial can clear.

The choice of comparator matters enormously here. Durvalumab plus gemcitabine and cisplatin received FDA accelerated approval in September 2022 as the first immunotherapy cleared for first-line biliary tract cancer, a disease where survival outcomes had been grim and largely unchanged for years. Running HARMONi-GI1 against that regimen rather than chemotherapy alone signals confidence from Akeso and Summit, and the OS win validates it. A placebo-controlled design would have been far safer statistically; a durvalumab-controlled design is an explicit claim of superiority over the established backbone.

The mechanism behind ivonescimab makes this result biologically coherent, even if it was not guaranteed. Ivonescimab is a tetravalent, Fc-silent bispecific antibody that simultaneously blocks PD-1-mediated immunosuppression and tumor angiogenesis via VEGF. Biliary tract cancers are notoriously immunosuppressive and vascularized tumors, so the dual blockade hypothesis has rational grounding. The data now suggest that rationale translates into survival benefit in a controlled setting, not just preclinical or early-phase signals.

For Summit’s clinical program, the immediate question is regulatory pathway. A positive OS readout from a randomized, double-blinded, multicenter registrational study in a cancer with poor prognosis gives Summit and Akeso a substantive package for global submissions. The single most consequential marker to track now is whether the FDA accepts a filing on this data and whether the agency treats the accelerated approval precedent for durvalumab as a floor or a ceiling for what it will demand in a full approval package for ivonescimab.

Source link: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/smmt-20260825.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.